Lonza Group Investor Presentation — January 2019

Document content

Lonza Achieved Another Excellent Full -Year Result in

2018 with 9% Organic Sales Growth and Strong

Profitability Driven by Healthcare Businesses

Richard Ridinger –CEO

Marc Funk –COO Pharma & Biotech

Rodolfo Savitzky –CFO

Corporate | FYR 2018 | 30 January 2019Table of Contents

FYR 2018 Corporate Overview

FYR 2018 Financial Summary

FYR 2018 Lonza Segments

Financial Summary and Qualitative Update Pharma & Biotech

Financial Summary and Qualitative Update Specialty Ingredients

Outlook 2019 & Mid -Term Guidance 2022

Events Calendar & Backup

Corporate | FYR 2018 | 30 January 2019 2Corporate

FYR 2018 Corporate Overview

Corporate | FYR 2018 | 30 January 2019Lonza Full -Year Results 2018 Highlights

Reporting another full -year with continued strong results

Corporate | FYR 2018 | 30 January 2019 CORE definition: See appendix

Lonza delivered its Full -Year 2018 results with sales of CHF 5.5 billion at a

record 27.3 % CORE EBITDA margin for Lonza’s continuing operations

Outperformance in Pharma & Biotech with 14% sales growth and margins up

260 bps was combined with positive momentum in Consumer Health division

Lonza continued to benefit from performance and synergies of the

successfully integrated Capsugel businesses

The challenging environment for cyclical parts of the Consumer & Resources

Protection portfolio continued to have a negative impact on the business

throughout the year while countermeasures are being implemented to

improve profitability

As a result of its strategic focus on the Healthcare Continuum®and thorough

Preview truncated — download the full document for the complete content.